Optiscan has been featured in Stockhead, The Australian and 11 News Corp mastheads in an article highlighting the initiation of a landmark clinical study evaluating the use of its InVue™ precision surgery and InForm™ digital pathology systems in head and neck cancer surgery.
The article highlights how the study - led by prominent Perth surgeon Dr Chady Sader at St John of God Murdoch Hospital - will recruit 50 patients and assess the real-time performance of Optiscan’s devices in treating oral, oropharyngeal, and other head and neck cancers. The study is a key milestone in validating Optiscan’s technology across major cancer indications.
The trial will also assess fluorescein sodium uptake in cancerous and healthy tissue, aligning with Optiscan’s collaboration with US-based Long Grove Pharmaceuticals and supporting future FDA submissions. Data generated will contribute to regulatory filings and the development of AI-driven imaging algorithms for oral cancer.
“From a patient care angle, the study is expected to demonstrate that Optiscan’s technology bridges the gap between traditional histopathology and immediate clinical decision-making, opening the way for surgeons to better assess tissue, determine completeness of resection and clearance of surgical margins, and refine surgical approaches in real time. This represents a paradigm shift in head and neck oncology, offering both patients and clinicians a safer, more efficient pathway to future diagnosis and treatment,” said Optiscan CEO Dr. Camile Farah.
Stockhead – Read the full article here
The Australian – Read the full article here
